The molecular pathology of Alzheimer's disease

Psychiatry

Volumn 7, Issue 1, 2008, Pages 1-5

  Yates, Darran ^a   McLoughlin, Declan M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

amyloid; amyloid precursor protein; dementia; plaques; tangles; tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; CAUSE OF DEATH; COGNITIVE DEFECT; COMORBIDITY; DISEASE ASSOCIATION; FUNCTIONAL ASSESSMENT; HUMAN; MENTAL DISEASE; NERVE CELL NECROSIS; NEUROCHEMISTRY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SYMPTOM; SYNAPSE;

EID: 37449020071     PISSN: 14761793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mppsy.2007.11.009     Document Type: Review

References (26)

1. Glenner G.G., Wong C.W., Quaranta V., and Eanes E.D. The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl Pathol 2 (1984) 357-369
2. Ballatore C., Lee V.M., and Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8 (2007) 663-672
3. Hardy J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis 9 Suppl (2006) 151-153
4. Goate A., Chartier-Harlin M.C., Mullan M., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349 (1991) 704-706
5. Mann D.M., Brown A., Prinja D., et al. An analysis of the morphology of senile plaques in Down's syndrome patients of different ages using immunocytochemical and lectin histochemical techniques. Neuropathol Appl Neurobiol 15 (1989) 317-329
6. Hutton M., Lendon C.L., Rizzu P., et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 18 (1998) 702-705
7. Bertram L., and Tanzi R.E. The current status of Alzheimer's disease genetics: what do we tell the patients?. Pharmacol Res 50 (2004) 385-396
8. Alzheimer disease & frontotemporal dementia mutation database. Available from:. http://www.molgen.ua.ac.be/ADMutations (accessed 25 October 2007)
9. Borchelt D.R., Thinakaran G., Eckman C.B., et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17 (1996) 1005-1013
10. Scheuner D., Eckman C., Jensen M., et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2 (1996) 864-870
11. Corder E.H., Saunders A.M., Strittmatter W.J., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 921-923
12. Poirier J., Davignon J., Bouthillier D., et al. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 342 (1993) 697-699
13. Buxbaum J.D., Liu K.N., Luo Y., et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 23 273 (1998) 697-699
14. Lammich S., Kojro E., Postina R., et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 96 (1999) 3922-3927
15. Takasugi N., Tomita T., Hayashi I., et al. The role of presenilin cofactors in the gamma-secretase complex. Nature 422 (2003) 438-441
16. Kimberly W.T., LaVoie M.J., Ostaszewski B.L., et al. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci USA 100 (2003) 6382-6387
17. Vassar R., Bennett B.D., Babu-Khan S., et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286 (1999) 735-741
18. Masters C.L., Cappai R., Barnham K.J., and Villemagne V.L. Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem 97 (2006) 1700-1725
19. Haass C., and Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8 (2007) 101-112
20. Wong G.T., Manfra D., Poulet F.M., et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279 (2004) 12876-12882
21. Siemers E., Skinner M., Dean R.A., et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 28 (2005) 126-132
22. Chang W.P., Koelsch G., Wong S., et al. In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. J Neurochem 89 (2004) 1409-1416
23. Luo Y., Bolon B., Kahn S., et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4 (2001) 231-232
24. Etcheberrigaray R., Tan M., Dewachter I., et al. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci USA 101 (2004) 11141-11146
25. Orgogozo J.M., Gilman S., Dartigues J.F., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 (2003) 46-54
26. Caccamo A., Oddo S., Tran L.X., and LaFerla F.M. Lithium reduces tau phosphorylation but not Abeta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol 170 (2007) 1669-1675